Replimune Reports Fiscal Third Quarter Financial Results and Provides Corporate Update
February 09, 2023 08:00 ET
|
Replimune Group Inc
Strengthened balance sheet raising gross $259 million through an upsized public offering in December, extending cash runway into H2 2025 and increasing operational and strategic flexibility Topline...
Replimune to Present at the Virtual SVB Securities Global Biopharma Conference
February 07, 2023 08:00 ET
|
Replimune Group Inc
WOBURN, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed...
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 04, 2023 08:05 ET
|
Replimune Group Inc
WOBURN, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic...
Replimune Appoints Former Sanofi U.S. Commercial Oncology Head, Chris Sarchi, as Chief Commercial Officer and Sushil Patel as Chief Strategy Officer
January 04, 2023 08:00 ET
|
Replimune Group Inc
WOBURN, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic...
Replimune to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023 08:00 ET
|
Replimune Group Inc
WOBURN, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic...
Replimune Announces Pricing of Public Offering
December 08, 2022 21:04 ET
|
Replimune Group Inc
BOSTON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic...
Replimune Announces Proposed Public Offering
December 07, 2022 16:04 ET
|
Replimune Group Inc
BOSTON, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic...
Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update
December 07, 2022 07:00 ET
|
Replimune Group Inc
RP1 combined with nivolumab continues to demonstrate deep and durable responses in patients with anti-PD1 failed melanoma Overall response rate (ORR) of 36% and complete response (CR) rate of 20%,...
Replimune Enters into Clinical Collaboration Agreement with Roche for the Development of RP3 In Colorectal Cancer and Hepatocellular Carcinoma
December 07, 2022 06:30 ET
|
Replimune Group Inc
RP3 will be developed in combination with atezolizumab and bevacizumab for the third-line treatment of colorectal cancer (CRC) and for the first- and second-line treatment of hepatocellular carcinoma...
Replimune to Present at the Piper Sandler 34th Annual Healthcare Conference
November 23, 2022 08:00 ET
|
Replimune Group Inc
WOBURN, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic...